OBJECTIVEAn association between variability in clinical parameters (HbA 1c , blood pressure, cholesterol, and uric acid) and risk of complications in type 2 diabetes has been reported. In this analysis, we investigated to what extent such variability is associated with overall quality of care.
RESEARCH DESIGN AND METHODSThe quality of care summary score (Q-score) represents a validated, overall quality of care indicator ranging between 0 and 40; the higher the score, the better the quality of care provided by the diabetes center. We identified patients with five or more measurements of clinical parameters after the assessment of the Q-score. Multiple linear regression analyses assessed the role of the Q-score in predicting the variability of the different parameters.
RESULTSOverall, 273,888 patients were analyzed. The variability of all the parameters systematically increased with decreasing Q-score values. At multivariate linear regression analysis, compared with a Q-score >25, a score <15 was associated with a significantly larger variation in HbA 1c , blood pressure, uric acid, total cholesterol, and LDL cholesterol and a lower variation in HDL cholesterol. The analysis of standardized b coefficients show that the Q-score has a larger impact on the variability of HbA 1c (0.34; P < 0.0001), systolic blood pressure (0.21; P < 0.0001), total cholesterol (0.21; P < 0.0001), and LDL cholesterol (0.20; P < 0.0001).
CONCLUSIONSThe variability of risk factors for diabetic complications is associated with quality of care. Quality of care improvement initiatives should be targeted to increase the achievement of the recommended target while reducing such variability.In Italy, a continuous improvement effort implemented by a network of diabetes clinics, i.e., AMD (Associazone Medici Diabetologi) Annals, has been in place since 2006 (1,2). After 8 years from the launch of the initiative, half of the diabetes clinics in Italy participated in the AMD-Annals initiative, caring for over one-sixth of all diagnosed patients. Process and intermediate outcome measures consistently improved, in parallel with a more intensive and appropriate use of pharmacologic treatments (3).